• Home
• Corporate Information
  • Management Team
  • • Management Team
    • Board of Directors
    • Committees of the Board
    • Senior Management Team
  • Job Vacancies
  • Links
• Investor Relations
  • Introduction
  • Financial Performance
  • • Key Financial Data
    • Reports & Accounts
  • Share Price
  • Share Charts
  • Securities in Issue
  • Press & News
  • • Press Releases
    • RNS Announcements
  • Shareholder Info
  • • FAQs
    • Financial Calendar
    • Shareholder Services
    • Contacts
    • Info Request
  • News Alert
  • • Alert Service
  • Presentations
  • AIM Rule 26
• Research & Development
  • Introduction
  • Product Pipeline
  • Intellectual Property Rights
  • Cannabinoid Medications
  • • Cannabinoids
    • Mechanism of Action
    • Intoxication
    • Sativex®
    • Cultivation
    • Clinical Trials Review
    • Clinical Publications
  • Cannabinoid Research
    Institute (CRI)
  • Advanced Dispensing
    System (ADS)
  • • Introduction to ADS
    • Drug Addiction
    • Other Applications of ADS
• FAQs
• News & Media
  • Press Releases
  • Notes for Editors
• Sativex®
• United States
• Contact Us

Search

Site Map

Privacy Statement

Disclosure & Disclaimer

		Latest News Tue, 18 Nov 2008 - Preliminary Results for the Year Ended 30 September 2008 more Wed, 22 Oct 2008 - Notification of Prelims more Wed, 01 Oct 2008 - Sativex® Phase III MS Spasticity Study Completes Patient Recruitment more Mon, 08 Sep 2008 - Positive Sativex® Study Confirms Long Term Efficacy in MS Neuropathic Pain more
© GW Pharmaceuticals 2009